Doxifluridine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Doxifluridine
Accession Number
DB12947
Type
Small Molecule
Groups
Investigational
Description

Doxifluridine has been investigated for the treatment of Stomach Cancer.

Structure
Thumb
Synonyms
Not Available
External IDs
RO 219738 / RO-219738
Categories
UNII
V1JK16Y2JP
CAS number
3094-09-5
Weight
Average: 246.1924
Monoisotopic: 246.065199677
Chemical Formula
C9H11FN2O5
InChI Key
ZWAOHEXOSAUJHY-ZIYNGMLESA-N
InChI
InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1
IUPAC Name
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-4-hydroxy-1,2-dihydropyrimidin-2-one
SMILES
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=C(F)C(O)=NC1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Doxifluridine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Doxifluridine.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Doxifluridine.Approved, Investigational, Withdrawn
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Anthrax immune globulin human.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Doxifluridine.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Doxifluridine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Doxifluridine.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Doxifluridine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Doxifluridine is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Doxifluridine.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Doxifluridine.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Doxifluridine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Doxifluridine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Doxifluridine.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Doxifluridine.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Doxifluridine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Doxifluridine.Approved, Investigational
FingolimodDoxifluridine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Doxifluridine is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Doxifluridine is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Doxifluridine.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Doxifluridine is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Human rabies virus immune globulin.Approved
INGN 201The risk or severity of adverse effects can be increased when Doxifluridine is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Doxifluridine is combined with INGN 225.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Doxifluridine is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Doxifluridine.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Leflunomide.Approved, Investigational
LipegfilgrastimDoxifluridine may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Doxifluridine.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Natalizumab.Approved, Investigational
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Doxifluridine.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Doxifluridine.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Doxifluridine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Doxifluridine.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Doxifluridine.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Doxifluridine.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Doxifluridine.Experimental
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Doxifluridine.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Rindopepimut.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Doxifluridine.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Rubella virus vaccine.Approved, Investigational
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Salmonella typhi ty21a live antigen.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Doxifluridine.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Doxifluridine is combined with SRP 299.Investigational
TacrolimusTacrolimus may increase the immunosuppressive activities of Doxifluridine.Approved, Investigational
TecemotideThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Tecemotide.Investigational
TG4010The risk or severity of adverse effects can be increased when Doxifluridine is combined with TG4010.Investigational
TofacitinibDoxifluridine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Doxifluridine.Approved, Investigational
Typhoid VaccineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Typhoid Vaccine.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Doxifluridine is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Yellow Fever Vaccine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0060406
KEGG Compound
C12739
PubChem Compound
18343
PubChem Substance
347829090
ChemSpider
17322
BindingDB
50132295
ChEBI
31521
ChEMBL
CHEMBL1130
Wikipedia
Doxifluridine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMalignant Neoplasm of Stomach2
4CompletedSupportive CareMalignant Neoplasm of Stomach1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.36 mg/mLALOGPS
logP-0.82ALOGPS
logP-0.8ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)6.2ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area102.59 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity51.55 m3·mol-1ChemAxon
Polarizability21.06 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 5'-deoxyribonucleosides. These are nucleosides in which the oxygen atom at the 5'position of the ribose moiety has been replaced by another atom. The nucleobases here are limited to purine, pyrimidine, and pyridine derivatives.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
5'-deoxyribonucleosides
Sub Class
Not Available
Direct Parent
5'-deoxyribonucleosides
Alternative Parents
Glycosylamines / Pyrimidones / Halopyrimidines / Aryl fluorides / Hydropyrimidines / Vinylogous amides / Tetrahydrofurans / Heteroaromatic compounds / Ureas / Secondary alcohols
show 9 more
Substituents
5'-deoxyribonucleoside / Glycosyl compound / N-glycosyl compound / Halopyrimidine / Pyrimidone / Aryl fluoride / Aryl halide / Pyrimidine / Hydropyrimidine / Heteroaromatic compound
show 20 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, pyrimidine 5'-deoxyribonucleoside (CHEBI:31521)

Drug created on October 20, 2016 19:32 / Updated on June 02, 2018 08:44